AHF: Gilead’s Greed Kills Promise of Lenacapavir for HIV Prevention

Gilead prices potential ‘game changer for HIV prevention’ at an eyepopping $28K per year

The U.S. Food and Drug Administration approved use of Gilead’s HIV treatment medication, lenacapavir, for use to prevent HIV infection earlier today, an action which was followed by news that Gilead intends to price the HIV prevention medication at over $28,000 per patient, per year. AIDS Healthcare Foundation (AHF) President Michael Weinstein sharply criticized Gilead’s outrageous pricing in the following statement:

“What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead’s greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV. Gilead is sacrificing control of HIV on the altar of their bottom line.”

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.3 million individuals across 48 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618031796/en/

“By pricing lenacapavir at over $28K per patient, per year, Gilead is sacrificing potential worldwide control and elimination of HIV on the altar of its bottom line.”